Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†

This randomized phase II study examined the use of vinflunine in combination with gemcitabine or carboplatin as first-line chemotherapy in cisplatin-ineligible patients with advanced urothelial carcinoma. Both doublets were feasible and offered a similar 77% disease control rate. Response rate (44%)...

Full description

Bibliographic Details
Main Authors: De Santis, M., Wiechno, P. J., Bellmunt, J., Lucas, C., Su, W.-C., Albiges, L., Lin, C.-C., Senkus-Konefka, E., Flechon, A., Mourey, L., Necchi, A., Loidl, W. C., Retz, M. M., Vaissière, N., Culine, S.
Format: Online
Language:English
Published: Oxford University Press 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769994/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769994/

Similar Items